Raymond Tu

Prof. Raymond Tu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2019 in Biomacromolecules
Verified
Journal Article
Closed access
LHLindsay K. Hill
Lindsay K. Hill
MMMichael Meleties
Michael Meleties
PKPriya Katyal
Priya Katyal
XXXuan Xie
Xuan Xie
EDErika Delgado-Fukushima
Erika Delgado-Fukushima
JMJin Kim Montclare
Jin Kim Montclare

4 February 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
AKAnkit D. Kanthe
Ankit D. Kanthe
MKMary Krause
Mary Krause
SZSongyan Zheng
Songyan Zheng
AIAndrew Ilott
Andrew Ilott
JLJinjiang Li
Jinjiang Li
RTRaymond Tu
Raymond Tu

27 August 2021 in Science Advances
Verified
Journal Article
Open access
AKAnkit Kanthe
Ankit Kanthe
AIAndrew Ilott
Andrew Ilott
MKMary Krause
Mary Krause
SZSongyan Zheng
Songyan Zheng
JLJinjiang Li
Jinjiang Li
RTRaymond Tu
Raymond Tu
Antibodies adsorbing to the interface are shown to dynamically reorient and unfold to define a quasi-equilibrium state.

3 July 2019 in Langmuir
Verified
Journal Article
Closed access
Sepideh RazaviSepideh Razavi
Sepideh Razavi
BLBinhua Lin
Binhua Lin
KLKa Yee C. Lee
Ka Yee C. Lee
RTRaymond Tu
Raymond Tu
IKIlona Kretzschmar
Ilona Kretzschmar

15 March 2018 in Biomacromolecules
Verified
Journal Article
Closed access
AOAndrew J. Olsen
Andrew J. Olsen
PKPriya Katyal
Priya Katyal
JHJennifer S. Haghpanah
Jennifer S. Haghpanah
MKMatthew B. Kubilius
Matthew B. Kubilius
RLRuipeng Li
Ruipeng Li
JMJin Kim Montclare
Jin Kim Montclare

26 July 2022 in Molecular Pharmaceutics
Verified
Journal Article
Open access
AKAnkit D. Kanthe
Ankit D. Kanthe
MCMiriam R. Carnovale
Miriam R. Carnovale
JKJoshua S. Katz
Joshua S. Katz
SJSusan Jordan
Susan Jordan
MKMary E. Krause
Mary E. Krause
RTRaymond Tu
Raymond Tu
Protein adsorption on surfaces can result in loss of drug product stability and efficacy during the production, storage, and administration of protein-based therapeutics. Surface-active agents (excipients) are typically added in protein formulations to prevent undesired interactions of proteins on surfaces and protein particle formation/aggregation in solution. The objective of this work is to understand the molecular-level competitive adsorption mechanism between the monoclonal antibody (mAb) and a commercially used excipient, polysorbate 80 (PS80), and a novel excipient, N-myristoyl phenylalanine-N-polyetheramine diamide (FM1000). The relative rate of adsorption of PS80 and FM1000 was studied by pendant bubble tensiometry. We find that FM1000 saturates the interface faster than PS80. Additionally, the surface-adsorbed amounts from X-ray reflectivity (XRR) measurements show that FM1000 blocks a larger percentage of interfacial area than PS80, indicating that a lower bulk FM1000 surface concentration is sufficient to prevent protein adsorption onto the air/water interface. XRR models reveal that with an increase in mAb concentration (0.5-2.5 mg/mL: IV based formulations), an increased amount of PS80 concentration (below critical micelle concentration, CMC) is required, whereas a fixed value of FM1000 concentration (above its relatively lower CMC) is sufficient to inhibit mAb adsorption, preventing mAb from co-existing with surfactants on the surface layer. With this observation, we show that the CMC of the surfactant is not the critical factor to indicate its ability to inhibit protein adsorption, especially for chemically different surfactants, PS80 and FM1000. Additionally, interface-induced aggregation studies indicate that at minimum surfactant concentration levels in protein formulations, fewer protein particles form in the presence of FM1000. Our results provide a mechanistic link between the adsorption of mAbs at the air/water interface and the aggregation induced by agitation in the presence of surfactants.